Zimmer Biomet Holdings (Zimmer Biomet Holdings) Cash-to-Debt

: 0.07 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zimmer Biomet Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zimmer Biomet Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zimmer Biomet Holdings's Cash-to-Debt or its related term are showing as below:

ZBH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.07 Max: 1.21
Current: 0.07

During the past 13 years, Zimmer Biomet Holdings's highest Cash to Debt Ratio was 1.21. The lowest was 0.05. And the median was 0.07.

ZBH's Cash-to-Debt is ranked worse than
93.86% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs ZBH: 0.07

Zimmer Biomet Holdings Cash-to-Debt Historical Data

The historical data trend for Zimmer Biomet Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zimmer Biomet Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.08

0.10

0.05

0.06

0.07

Zimmer Biomet Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.06	0.06	0.05	0.05	0.07

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Cash-to-Debt falls into.

Zimmer Biomet Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zimmer Biomet Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	415.8	/	(900	+	5012.6)
	=	0.07

Zimmer Biomet Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	415.8	/	(900	+	5012.6)
	=	0.07

Zimmer Biomet Holdings (NYSE:ZBH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zimmer Biomet Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Executives

Syed A. Jafry	director	345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli	director	C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley	director
Robert Hagemann	director	3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson	director	2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard	director	711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps	officer: Assoc. Gen. Counsel, Corp. Sec	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van	officer: Pres, Europe, M. East & Africa	345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato	officer: VP, Controller & CAO	C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi	officer: President, Asia Pacific	345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler	officer: SVP and CHRO	345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson	officer: SVP & CSO	345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson	director, officer: President and CEO	ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau	officer: Group President	345 E. MAIN STREET, WARSAW IN 46580